April 2024
1. NEUEN BL, Tuttle KR, Vaduganathan M
   Accelerated Risk-Based Implementation of Guideline-Directed Medical Therapy for Type 2 Diabetes and Chronic Kidney Disease.
   Circulation. 2024;149:1238-1240.
   

   >> Share

   
   
2. BLOOD AJ, Chang LS, Hassan S, Chasse J, et al
   Randomized Evaluation of a Remote Management Program to Improve Guideline-directed Medical Therapy: The Diabetes Remote Intervention to Improve Use of Evidence-based Medications (DRIVE) Trial.
   Circulation. 2024 Apr 7. doi: 10.1161/CIRCULATIONAHA.124.069494.
   

   >> Share

   
   March 2024
3. BILLING AM, Kim YC, Gullaksen S, Schrage B, et al
   Metabolic Communication by SGLT2 Inhibition.
   Circulation. 2024;149:860-884.
   

   >> Share

   
   
4. GABA P, Sabik JF, Murphy SA, Bellavia A, et al
   Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Main Disease With or Without Diabetes: Findings From a Pooled Analysis of 4 Randomized Clinical Trials.
   Circulation. 2024 Mar 11. doi: 10.1161/CIRCULATIONAHA.123.065571.
   

   >> Share

   
   February 2024
5. GREEN JB, Everett BM, Ghosh A, Younes N, et al
   Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study).
   Circulation. 2024 Feb 12. doi: 10.1161/CIRCULATIONAHA.123.066604.
   

   >> Share

   
   January 2024
6. LI Y, Liu Z, Han X, Liang F, et al
   Dynamics of Endothelial Cell Generation and Turnover in Arteries During Homeostasis and Diseases.
   Circulation. 2024;149:135-154.
   

   >> Share

   
   December 2023
7. OSTERGAARD L, Olesen JB, Petersen JK, Nielsen LS, et al
   Arterial Thromboembolism in Patients With Atrial Fibrillation and CHA(2)DS(2)-VASc 1: A Nationwide Study.
   Circulation. 2023 Dec 28. doi: 10.1161/CIRCULATIONAHA.123.066477.
   

   >> Share

   
   
8. ZHAN J, Jin K, Xie R, Fan J, et al
   Ago2 Protects Against Diabetic Cardiomyopathy by Activating Mitochondrial Gene Translation.
   Circulation. 2023 Dec 21. doi: 10.1161/CIRCULATIONAHA.123.065546.
   

   >> Share

   
   
9. GALLAGHER KA, Mills JL, Armstrong DG, Conte MS, et al
   Current Status and Principles for the Treatment and Prevention of Diabetic Foot Ulcers in the Cardiovascular Patient Population: A Scientific Statement From the American Heart Association.
   Circulation. 2023 Dec 14. doi: 10.1161/CIR.0000000000001192.
   

   >> Share

   
   November 2023
10. XIE SY, Liu SQ, Zhang T, Shi WK, et al
    USP28 Serves as a Key Suppressor of Mitochondrial Morphofunctional Defects and Cardiac Dysfunction in the Diabetic Heart.
    Circulation. 2023 Nov 23. doi: 10.1161/CIRCULATIONAHA.123.065603.
    

    >> Share

    
    
11. NEUEN BL, Heerspink HJL, Vart P, Claggett BL, et al
    Estimated Lifetime Cardiovascular, Kidney and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Non-steroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.
    Circulation. 2023 Nov 12. doi: 10.1161/CIRCULATIONAHA.123.067584.
    

    >> Share

    
    
12. PATEL KV, Segar MW, Klonoff DC, Khan MS, et al
    Optimal Screening for Predicting and Preventing the Risk of Heart Failure Among Adults With Diabetes Without Atherosclerotic Cardiovascular Disease: a Pooled Cohort Analysis.
    Circulation. 2023 Nov 11. doi: 10.1161/CIRCULATIONAHA.123.067530.
    

    >> Share

    
    September 2023
13. JEX N, Greenwood JP, Cubbon RM, Rider OJ, et al
    Association Between Type 2 Diabetes and Changes in Myocardial Structure, Contractile Function, Energetics, and Blood Flow Before and After Aortic Valve Replacement in Patients With Severe Aortic Stenosis.
    Circulation. 2023 Sep 25. doi: 10.1161/CIRCULATIONAHA.122.063444.
    

    >> Share

    
    August 2023
14. JANUZZI JL, Mohebi R, Liu Y, Sattar N, et al
    Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial.
    Circulation. 2023;148:651-660.
    

    >> Share

    
    
15. BORLAUG BA, Reddy YNV, Braun A, Sorimachi H, et al
    Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The CAMEO-DAPA Trial.
    Circulation. 2023 Aug 3. doi: 10.1161/CIRCULATIONAHA.123.065134.
    

    >> Share

    
    June 2023
16. OZKAN B, Ndumele CE
    Addressing Cardiovascular Risk in Diabetes: It's More Than the Sugar.
    Circulation. 2023;147:1887-1890.
    

    >> Share

    
    
17. 
    Correction to: Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial.
    Circulation. 2023;147:e720.
    

    >> Share

    
    May 2023
18. KWAN TW, Wong SS, Hong Y, Kanaya AM, et al
    Epidemiology of Diabetes and Atherosclerotic Cardiovascular Disease Among Asian American Adults: Implications, Management, and Future Directions: A Scientific Statement From the American Heart Association.
    Circulation. 2023 May 8. doi: 10.1161/CIR.0000000000001145.
    

    >> Share

    
    
19. SATTAR N, McMurray J, Boren J, Rawshani A, et al
    Years of Cardiovascular Complications and Risk Factors in Patients With Type 2 Diabetes: A Nationwide Swedish Cohort Study.
    Circulation. 2023 May 8. doi: 10.1161/CIRCULATIONAHA.122.063374.
    

    >> Share

    
    April 2023
20. SADOSHIMA J
    Caveolin-3 Nitration Drives Insulin Resistance in Prediabetic Hearts.
    Circulation. 2023;147:1180-1182.
    

    >> Share

    
    
21. WONG EKC, Demers C
    Letter by Wong and Demers Regarding Article, "Efficacy and Safety of Dapagliflozin According to Frailty in Patients With Heart Failure: A Prespecified Analysis of the DELIVER Trial".
    Circulation. 2023;147:1118.
    

    >> Share

    
    March 2023
22. HINKLE SN, Schisterman EF, Liu D, Pollack AZ, et al
    Pregnancy Complications and Long-Term Mortality in a Diverse Cohort.
    Circulation. 2023;147:1014-1025.
    

    >> Share

    
    
23. TABAK AG, Sattar N, Kivimaki M
    Response by Tabak et al to Letters Regarding Article, "Risk of Macrovascular and Microvascular Disease in Diabetes Diagnosed Using Oral Glucose Tolerance Test With and Without Confirmation by Hemoglobin A1c: The Whitehall II Cohort Study".
    Circulation. 2023;147:988-989.
    

    >> Share

    
    
24. DENG L, Chen Y, Deng W
    Letter by Deng et al Regarding Article, "Risk of Macrovascular and Microvascular Disease in Diabetes Diagnosed Using Oral Glucose Tolerance Test With and Without Confirmation by Hemoglobin A1c: The Whitehall II Cohort Study".
    Circulation. 2023;147:985-986.
    

    >> Share

    
    
25. SCHMIDT MI, Bracco PA, Duncan BB
    Letter by Schmidt et al Regarding Article, "Risk of Macrovascular and Microvascular Disease in Diabetes Diagnosed Using Oral Glucose Tolerance Test With and Without Confirmation by Hemoglobin A1c: The Whitehall II Cohort Study".
    Circulation. 2023;147:987.
    

    >> Share

    
    
26. MENG Z, Zhang Z, Zhao J, Liu C, et al
    Nitrative Modification of Caveolin-3: A Novel Mechanism of Cardiac Insulin Resistance and a Potential Therapeutic Target Against Ischemic Heart Failure in Prediabetic Animals.
    Circulation. 2023 Mar 8. doi: 10.1161/CIRCULATIONAHA.122.063073.
    

    >> Share

    
    
27. VERMA S, Alamuddin N, Alawadi F, Alkandari H, et al
    Prevalence of Diabetes and Cardiovascular Risk in the Middle East and Africa: Primary Results of the PACT-MEA Study.
    Circulation. 2023 Mar 6. doi: 10.1161/CIRCULATIONAHA.123.064345.
    

    >> Share

    
    
28. HAHN VS, Petucci C, Kim MS, Bedi KC Jr, et al
    Myocardial Metabolomics of Human Heart Failure With Preserved Ejection Fraction.
    Circulation. 2023 Mar 1. doi: 10.1161/CIRCULATIONAHA.122.061846.
    

    >> Share

    
    February 2023
29. GERSTEIN HC, Li Z, Ramasundarahettige C, Baek S, et al
    Exploring the Relationship Between Efpeglenatide Dose and Cardiovascular Outcomes in Type 2 Diabetes: Insights From the AMPLITUDE-O Trial.
    Circulation. 2023 Feb 20. doi: 10.1161/CIRCULATIONAHA.122.063716.
    

    >> Share

    
    
30. SAWAMI K, Tanaka A, Node K
    Letter by Sawami et al Regarding Article, "Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF)".
    Circulation. 2023;147:e73-e74.
    

    >> Share

    
    January 2023
31. CHEN S, Wang Q, Christodoulou A, Mylonas N, et al
    Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Reduces Infarct Size Independently of Sodium Glucose Cotransporter-2.
    Circulation. 2023;147:276-279.
    

    >> Share

    
    December 2022
32. GYLDENKERNE C, Maeng M, Kjoller-Hansen L, Maehara A, et al
    Coronary Artery Lesion Lipid Content and Plaque Burden in Diabetic and Nondiabetic Patients: PROSPECT II.
    Circulation. 2022 Dec 16. doi: 10.1161/CIRCULATIONAHA.122.061983.
    

    >> Share

    
    
33. SCHOLTES RA, Hesp AC, Mosterd CM, Geurts F, et al
    Kidney Hemodynamic Effects of Angiotensin Receptor Blockade, Sodium-Glucose Cotransporter-2 Inhibition Alone, and Their Combination: A Crossover Randomized Trial in People With Type 2 Diabetes.
    Circulation. 2022;146:1895-1897.
    

    >> Share

    
    
34. MARX N, Husain M, Lehrke M, Verma S, et al
    GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes.
    Circulation. 2022;146:1882-1894.
    

    >> Share

    
    November 2022
35. GAO P, Cao M, Jiang X, Wang X, et al
    Cannabinoid Receptor 2-Centric Molecular Feedback Loop Drives Necroptosis in Diabetic Heart Injuries.
    Circulation. 2022 Nov 30. doi: 10.1161/CIRCULATIONAHA.122.059304.
    

    >> Share

    
    
36. TONELLI M, Straus S
    Increasing Societal Benefit From Cardiovascular Drugs.
    Circulation. 2022;146:1627-1635.
    

    >> Share

    
    
37. VERMA S, Dhingra NK, Butler J, Anker SD, et al
    Empagliflozin in Black Versus White Patients with Heart Failure: Analysis of EMPEROR-Pooled.
    Circulation. 2022 Nov 7. doi: 10.1161/CIRCULATIONAHA.122.062644.
    

    >> Share

    
    
38. WANG X, Vaduganathan M, Claggett BL, Hegde SM, et al
    Sex Differences in Characteristics, Outcomes and Treatment Response with Dapagliflozin across the Range of Ejection Fraction in Patients with Heart Failure: Insights from DAPA-HF and DELIVER.
    Circulation. 2022 Nov 7. doi: 10.1161/CIRCULATIONAHA.122.062832.
    

    >> Share

    
    
39. CONNELLY KA, Mazer CD, Puar P, Teoh H, et al
    Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial.
    Circulation. 2022 Nov 6. doi: 10.1161/CIRCULATIONAHA.122.062769.
    

    >> Share

    
    
40. PACKER M
    Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis.
    Circulation. 2022;146:1383-1405.
    

    >> Share

    
    October 2022
41. GAZIANO L, Sun L, Arnold M, Bell S, et al
    Mild-to-Moderate Kidney Dysfunction and Cardiovascular Disease: Observational and Mendelian Randomization Analyses.
    Circulation. 2022 Oct 31. doi: 10.1161/CIRCULATIONAHA.122.060700.
    

    >> Share

    
    
42. ZWECK E, Scheiber D, Schultheiss HP, Kuss O, et al
    Impaired Myocardial Mitochondrial Respiration in Humans With Prediabetes: A Footprint of Prediabetic Cardiomyopathy.
    Circulation. 2022;146:1189-1191.
    

    >> Share

    
    September 2022
43. JIN L, Geng L, Ying L, Shu L, et al
    FGF21-Sirtuin 3 Axis Confers the Protective Effects of Exercise Against Diabetic Cardiomyopathy by Governing Mitochondrial Integrity.
    Circulation. 2022 Sep 22:101161CIRCULATIONAHA122059631.
    

    >> Share

    
    August 2022
44. TABAK AG, Brunner EJ, Lindbohm JV, Singh-Manoux A, et al
    Risk of Macrovascular and Microvascular Disease in Diabetes Diagnosed Using Oral Glucose Tolerance Test With and Without Confirmation by Hemoglobin A1c: The Whitehall II Cohort Study.
    Circulation. 2022 Aug 25:101161CIRCULATIONAHA122059430.
    

    >> Share

    
    
45. COSENTINO F, Cannon CP, Frederich R, Cherney DZI, et al
    Cardiorenal Outcomes With Ertugliflozin by Baseline Metformin Use: Post Hoc Analyses of the VERTIS CV Trial.
    Circulation. 2022;146:652-654.
    

    >> Share

    
    
46. UMANATH K, Testani JM, Lewis JB
    "Dip" in eGFR: Stay the Course With SGLT-2 Inhibition.
    Circulation. 2022;146:463-465.
    

    >> Share

    
    July 2022
47. ANKER SD, Usman MS, Butler J
    SGLT2 Inhibitors: From Antihyperglycemic Agents to All-Around Heart Failure Therapy.
    Circulation. 2022;146:299-302.
    

    >> Share

    
    
48. LEE MMY, Gillis KA, Brooksbank KJM, Allwood-Spiers S, et al
    Effect of Empagliflozin on Kidney Biochemical and Imaging Outcomes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure with Reduced Ejection Fraction (SUGAR-DM-HF).
    Circulation. 2022;146:364-367.
    

    >> Share

    
    
49. O'SULLIVAN JW, Raghavan S, Marquez-Luna C, Luzum JA, et al
    Polygenic Risk Scores for Cardiovascular Disease: A Scientific Statement From the American Heart Association.
    Circulation. 2022 Jul 18:101161CIR0000000000001077.
    

    >> Share

    
    
50. LAM CSP, Gerstein HC
    Response by Lam and Gerstein to Letter Regarding Article, "Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial".
    Circulation. 2022;146:e7.
    

    >> Share

    
    
51. GROOTHOF D, Post A, Bakker SJL
    Letter by Groothof et al Regarding Article, "Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial".
    Circulation. 2022;146:e5-e6.
    

    >> Share

    
    
52. EICHELMANN F, Sellem L, Wittenbecher C, Jager S, et al
    Deep Lipidomics in Human Plasma: Cardiometabolic Disease Risk and Effect of Dietary Fat Modulation.
    Circulation. 2022;146:21-35.
    

    >> Share

    
    June 2022
53. SCHULZE PC, Bogoviku J, Westphal J, Aftanski P, et al
    Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF).
    Circulation. 2022 Jun 29:101161CIRCULATIONAHA122059038.
    

    >> Share

    
    
54. FILIPPATOS G, Butler J, Farmakis D, Zannad F, et al
    Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes.
    Circulation. 2022 Jun 28:101161CIRCULATIONAHA122059785.
    

    >> Share

    
    
55. RAWSHANI A, Sattar N, McGuire DK, Wallstrom O, et al
    Left-Sided Degenerative Valvular Heart Disease in Type 1 and Type 2 Diabetes.
    Circulation. 2022 Jun 9. doi: 10.1161/CIRCULATIONAHA.121.058072.
    

    >> Share

    
    May 2022
56. GERSTEIN HC
    Shouldn't Preventing Type 2 Diabetes Also Prevent Its Long-Term Consequences?
    Circulation. 2022;145:1642-1644.
    

    >> Share

    
    
57. GOLDBERG RB, Orchard TJ, Crandall JP, Boyko EJ, et al
    Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study.
    Circulation. 2022 May 23. doi: 10.1161/CIRCULATIONAHA.121.056756.
    

    >> Share

    
    
58. SELVARAJ S, Fu Z, Jones P, Kwee LC, et al
    Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure with Reduced Ejection Fraction: DEFINE-HF.
    Circulation. 2022 May 23. doi: 10.1161/CIRCULATIONAHA.122.060402.
    

    >> Share

    
    
59. FURTADO RHM, Raz I, Goodrich EL, Murphy SA, et al
    Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial.
    Circulation. 2022 May 5. doi: 10.1161/CIRCULATIONAHA.121.058103.
    

    >> Share

    
    April 2022
60. ADAMSON C, Docherty KF, Heerspink HJL, de Boer RA, et al
    Initial Decline ("dip") in Estimated Glomerular Filtration Rate Following Initiation of Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction: Insights from DAPA-HF.
    Circulation. 2022 Apr 20. doi: 10.1161/CIRCULATIONAHA.121.058910.
    

    >> Share

    
    
61. VASAN RS, Enserro DM, Xanthakis V, Beiser AS, et al
    Temporal Trends in the Remaining Lifetime Risk of Cardiovascular Disease Among Middle-Aged Adults Across 6 Decades: The Framingham Study.
    Circulation. 2022 Apr 18. doi: 10.1161/CIRCULATIONAHA.121.057889.
    

    >> Share

    
    
62. NEUEN BL, Oshima M, Agarwal R, Arnott C, et al
    Sodium-glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People with Type 2 diabetes: A Meta-analysis of Individual Participant Data from Randomized Controlled Trials.
    Circulation. 2022 Apr 8. doi: 10.1161/CIRCULATIONAHA.121.057736.
    

    >> Share

    
    
63. SLIZ E, Shin J, Ahmad S, Williams DM, et al
    Circulating Metabolome and White Matter Hyperintensities in Women and Men.
    Circulation. 2022;145:1040-1052.
    

    >> Share

    
    March 2022
64. CORTES V, Eckel RH
    Insulin and Bile Acids in Cholesterol Homeostasis: New Players in Diabetes-Associated Atherosclerosis.
    Circulation. 2022;145:983-986.
    

    >> Share

    
    February 2022
65. SEMOVA I, Levenson AE, Krawczyk J, Bullock K, et al
    Insulin Prevents Hypercholesterolemia by Suppressing 12a-Hydroxylated Bile Acid Production.
    Circulation. 2022 Feb 23. doi: 10.1161/CIRCULATIONAHA.120.045373.
    

    >> Share

    
    
66. 
    Correction to: Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials.
    Circulation. 2022;145:e641.
    

    >> Share

    
    January 2022
67. JOSEPH JJ, Deedwania P, Acharya T, Aguilar D, et al
    Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association.
    Circulation. 2022 Jan 10:CIR0000000000001040. doi: 10.1161/CIR.0000000000001040.
    

    >> Share

    
    December 2021
68. SHAMAN AM, Bain SC, Bakris GL, Buse JB, et al
    Effect of the Glucagon-like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: a Pooled Analysis of SUSTAIN 6 and LEADER Trials.
    Circulation. 2021 Dec 14. doi: 10.1161/CIRCULATIONAHA.121.055459.
    

    >> Share

    
    
69. PATEL KV, Segar MW, Lavie CJ, Kondamudi N, et al
    Diabetes Status Modifies the Association Between Different Measures of Obesity and Heart Failure Risk Among Older Adults: A Pooled Analysis of Community-Based NHLBI Cohorts.
    Circulation. 2021 Dec 3. doi: 10.1161/CIRCULATIONAHA.121.055830.
    

    >> Share

    
    November 2021
70. LAM CSP, Ramasundarahettige C, Branch KRH, Sattar N, et al
    Efpeglenatide and Clinical Outcomes with and without Concomitant Sodium-Glucose Co-Transporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial.
    Circulation. 2021 Nov 14. doi: 10.1161/CIRCULATIONAHA.121.057934.
    

    >> Share

    
    
71. FILIPPATOS G, Anker SD, Agarwal R, Ruilope LM, et al
    Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses from the FIGARO-DKD Trial.
    Circulation. 2021 Nov 13. doi: 10.1161/CIRCULATIONAHA.121.057983.
    

    >> Share

    
    October 2021
72. MAJITHIA A, Bhatt DL, Friedman AN, Miller M, et al
    Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients with Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL.
    Circulation. 2021 Oct 28. doi: 10.1161/CIRCULATIONAHA.121.055560.
    

    >> Share

    
    September 2021
73. EDGAR L, Akbar N, Braithwaite AT, Krausgruber T, et al
    Hyperglycemia Induces Trained Immunity in Macrophages and Their Precursors and Promotes Atherosclerosis.
    Circulation. 2021;144:961-982.
    

    >> Share

    
    June 2021
74. MORRIS AA, Testani JM, Butler J
    Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Racial Differences and a Potential for Reducing Disparities.
    Circulation. 2021;143:2329-2331.
    

    >> Share

    
    March 2021
75. PATEL RB, Ter Maaten JM, Ferreira JP, McCausland FR, et al
    Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials.
    Circulation. 2021;143:949-958.
    

    >> Share

    
    February 2021
76. GOFF DC JR, Khan SS, Lloyd-Jones D, Arnett DK, et al
    Bending the Curve in Cardiovascular Disease Mortality: Bethesda + 40 and Beyond.
    Circulation. 2021;143:837-851.
    

    >> Share

    
    January 2021
77. VIRANI SS, Alonso A, Aparicio HJ, Benjamin EJ, et al
    Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association.
    Circulation. 2021 Jan 27:CIR0000000000000950. doi: 10.1161/CIR.0000000000000950.
    

    >> Share

    
    
78. KOSIBOROD M
    Diamonds in the Rough: The Incredible-but-True Story of Sodium Glucose Cotransporter 2 Inhibitors in Treatment of Heart Failure.
    Circulation. 2021;143:350-353.
    

    >> Share

    
    
79. PETERSON BE, Bhatt DL, Steg PG, Miller M, et al
    Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses.
    Circulation. 2021;143:33-44.
    

    >> Share

    
    August 2020
80. MORDI NA, Mordi IR, Singh JS, McCrimmon RJ, et al
    Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination with Loop Diuretics in Patients with Type 2 Diabetes and Chronic Heart Failure: The RECEDE-CHF Trial.
    Circulation. 2020 Aug 29. doi: 10.1161/CIRCULATIONAHA.120.048739.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share